Latest From Pharmaxis Ltd.
A Milbank Quarterly study and a Pink Sheet analysis show that disagreement between the US FDA and its advisory committee meetings doesn't happen often; it is even rarer for the agency to approve a drug against the advice from a panel.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
The latest drug development news and highlights from our US FDA Performance Tracker.
Pulmonary-Allergy Drugs Advisory Committee votes 9-7 that the benefits of Pharmaxis' cystic fibrosis drug outweigh its risks, leaving the FDA with a muddled verdict.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Hepatic (Liver)
- Respiratory, Pulmonary
- Praxis Pharmaceuticals Australia Pty. Ltd.
- Pharmaxis Pty Ltd.
- Parent & Subsidiaries
- Pharmaxis Ltd.
- Senior Management
Gary Phillips, CEO
David McGarvey, CFO & Secretary
- Contact Info
Phone: (61) 2 9454 7200
20 Rodborough Rd.
Frenchs Forest, NSW 2086
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.